Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 31 of 38, showing 5 Applications out of 189 total, starting on record 151, ending on 155

# Protocol No Study Title Investigator(s) & Site(s)

151.

ECCT/23/08/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Nduba Videlis
Site(s) in Kenya
1. Getrudes Children Hospital (Nairobi City county)
2. KEMRI/CRDR (Siaya county)
3. Kombewa CRC (Kisumu county)
4. Kondele Childrens Hospital (Kisumu county)
 
View

152.

ECCT/23/01/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Ogutu Bernhards Ragama
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county)
4. Kombewa CRC (Kisumu county)
 
View

153.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
View

154.

ECCT/14/09/01   Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa
    An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa.   Study number: MALARIA-076 (200599)   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project
 
View

155.

ECCT/23/09/04   GBT440-038Open-Label Extension
    An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children Hospital (Nairobi City county)
2. Kenya Medical Research Institute (KEMRI), Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI CRDR SIAYA within Siaya County Referral Hospital Grounds (Siaya county)
4. Strathmore University Medical Center, Centre for Research in Therapeutic Sciences (Nairobi City county)
 
View